search
Back to results

Tailored Antiplatelet Therapy Following PCI (TAILOR-PCI)

Primary Purpose

Coronary Artery Disease, Acute Coronary Syndrome, Stenosis

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Clopidogrel
Ticagrelor
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring percutaneous coronary intervention, angioplasty

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion

  • Patient >18 years of age
  • Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)
  • Patient is eligible for PCI
  • Patient is willing and able to provide informed written consent

5.3 Exclusion

  • Patient not able to receive 12 months of dual anti-platelet therapy
  • Failure of index PCI
  • Patient or physician refusal to enroll in the study
  • Patient with known CYP2C19 genotype prior to randomization
  • Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
  • Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery
  • Serum creatinine >2.5 mg/dL within 7 days of index procedure
  • Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.
  • History of intracranial hemorrhage
  • Known hypersensitivity to clopidogrel or ticagrelor or any of its components
  • Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint
  • Patient previously enrolled in this study
  • Patient is pregnant, lactating, or planning to become pregnant within 12 months
  • Patient has received an organ transplant or is on a waiting list for an organ transplant
  • Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure
  • Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)
  • Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)
  • Concomitant use of simvastatin/lovastatin > 40 mg qd
  • Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)
  • Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer)
  • Known history of severe hepatic impairment
  • Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  • Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding
  • Inability to take aspirin at a dosage of 100 mg or less
  • Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)

Sites / Locations

  • Mayo Clinic in Arizona
  • Sharp HealthCare
  • Zuckerberg San Francisco General
  • Mayo Clinic in Florida
  • NCH Heart Institute
  • NorthShore University Health System
  • Loyola University Medical Center
  • St. Elizabeth Healthcare
  • Henry Ford Hospital
  • Essentia Institute of Rural Health
  • Minneapolis Heart Institute
  • University of Minnesota
  • Mayo Clinic in Rochester
  • The University of Mississippi Medical Center
  • Albany Medical College
  • The Feinstein Institute for Medical Research
  • Winthrop University Hospital
  • New York University Langone Medical Center
  • Columbia University Medical Center
  • Cardiology Associates of Schenectady
  • Rhode Island Hospital
  • The Miriam Hospital
  • Greenville Health System
  • MHS, Eau Claire
  • Mayo Clinic Health System
  • Aurora Health Care
  • Vancouver General Hospital, UBC Division of Cardiology
  • University of Ottawa Heart Institute
  • Thunder Bay Regional Health Sciences Centre
  • Humber River Hospital
  • Sunnybrook Health Services Center
  • St Michael's Hospital
  • Toronto General Hospital - UHN
  • Regina General Hospital
  • Konyang University College of Medicine
  • Chonnam National University Hospital
  • Ajou University Hospital
  • Chung-Ang University Hospital
  • Hospital de Especialidades, Centro Medico Nacional 'La Raza'
  • Hospital REgional No. 1
  • Hospital de Cardiologia, Centro Medico Nacional Siglo XXI

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Genotype-Guided Therapy

Conventional Therapy

Arm Description

Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.

Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.

Outcomes

Primary Outcome Measures

Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan.
Occurrence of the a Major Adverse Cardiovascular Event
Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis.

Secondary Outcome Measures

Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan
Thrombolysis in Myocardial Infarction Major or Minor Bleeding
Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding

Full Information

First Posted
December 3, 2012
Last Updated
October 11, 2021
Sponsor
Mayo Clinic
Collaborators
Spartan Bioscience Inc., Applied Health Research Centre, National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01742117
Brief Title
Tailored Antiplatelet Therapy Following PCI
Acronym
TAILOR-PCI
Official Title
Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
October 31, 2020 (Actual)
Study Completion Date
October 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
Spartan Bioscience Inc., Applied Health Research Centre, National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
Detailed Description
TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor 90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite endpoint of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis (primary endpoints) in CYP2C19 reduced function allele patients. Patients who undergo PCI will be randomized to a conventional therapy arm (i.e., to receive clopidogrel 75 mg once daily without prospective genotyping guidance) versus a prospective CYP2C19 genotype-based anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 *2 or *3 reduced function allele patients, clopidogrel 75 mg once daily in non-*2 or -*3 CYP2C19 patients). Buccal swabs will be obtained for those subjects randomized to the prospective genotyping arm. All subjects will have a blood sample drawn for DNA analysis but genotyping using these DNA samples will be performed only after completion of the duration of anti-platelet therapy (i.e., after one year). The primary endpoints will be assessed prospectively and will be compared between the conventional arm and the prospective genotyping arm among those identified as reduced function CYP2C19 allele carriers according to the 1-year genotype results.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Keywords
percutaneous coronary intervention, angioplasty

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5276 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Genotype-Guided Therapy
Arm Type
Experimental
Arm Description
Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.
Arm Title
Conventional Therapy
Arm Type
Active Comparator
Arm Description
Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.
Intervention Type
Drug
Intervention Name(s)
Clopidogrel
Other Intervention Name(s)
Plavix
Intervention Description
One 75 mg tablet per day by mouth for one year
Intervention Type
Drug
Intervention Name(s)
Ticagrelor
Other Intervention Name(s)
Brilinta
Intervention Description
One 90 mg tablet twice per day by mouth for one year
Primary Outcome Measure Information:
Title
Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
Description
Number of subjects who experienced major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis in subjects identified as CPY2C19 LOF carriers by TaqMan.
Time Frame
1 year after percutaneous coronary intervention (PCI)
Title
Occurrence of the a Major Adverse Cardiovascular Event
Description
Number of subjects to experience a major adverse cardiovascular event as defined as cardiovascular death, myocardial infarction, stroke, severe recurrent ischemia, and stent thrombosis.
Time Frame
Approximately 3 years after percutaneous coronary intervention (PCI)
Secondary Outcome Measure Information:
Title
Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.
Description
Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding in subjects identified as CYP2C19 LOF carriers by TaqMan
Time Frame
1 year after percutaneous coronary intervention (PCI)
Title
Thrombolysis in Myocardial Infarction Major or Minor Bleeding
Description
Number of subjects that experienced thrombolysis in myocardial infarction major or minor bleeding
Time Frame
Approximately 3 years after percutaneous coronary intervention (PCI)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Patient >18 years of age Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD) Patient is eligible for PCI Patient is willing and able to provide informed written consent 5.3 Exclusion Patient not able to receive 12 months of dual anti-platelet therapy Failure of index PCI Patient or physician refusal to enroll in the study Patient with known CYP2C19 genotype prior to randomization Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery Serum creatinine >2.5 mg/dL within 7 days of index procedure Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure. History of intracranial hemorrhage Known hypersensitivity to clopidogrel or ticagrelor or any of its components Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint Patient previously enrolled in this study Patient is pregnant, lactating, or planning to become pregnant within 12 months Patient has received an organ transplant or is on a waiting list for an organ transplant Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.) Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor) Concomitant use of simvastatin/lovastatin > 40 mg qd Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine) Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer) Known history of severe hepatic impairment Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding Inability to take aspirin at a dosage of 100 mg or less Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naveen Pereira, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael E Farkouh, MD
Organizational Affiliation
Toronto General Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kent R Bailey, PhD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Arizona
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Facility Name
Sharp HealthCare
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Zuckerberg San Francisco General
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Facility Name
Mayo Clinic in Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
NCH Heart Institute
City
Naples
State/Province
Florida
ZIP/Postal Code
34102
Country
United States
Facility Name
NorthShore University Health System
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
Loyola University Medical Center
City
Maywood
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
St. Elizabeth Healthcare
City
Crestview Hills
State/Province
Kentucky
ZIP/Postal Code
41017
Country
United States
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Essentia Institute of Rural Health
City
Duluth
State/Province
Minnesota
ZIP/Postal Code
55805
Country
United States
Facility Name
Minneapolis Heart Institute
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407
Country
United States
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
The University of Mississippi Medical Center
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Facility Name
Albany Medical College
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Facility Name
The Feinstein Institute for Medical Research
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
Winthrop University Hospital
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
Facility Name
New York University Langone Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Cardiology Associates of Schenectady
City
Schenectady
State/Province
New York
ZIP/Postal Code
12309
Country
United States
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
The Miriam Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States
Facility Name
Greenville Health System
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
MHS, Eau Claire
City
Eau Claire
State/Province
Wisconsin
ZIP/Postal Code
54702
Country
United States
Facility Name
Mayo Clinic Health System
City
La Crosse
State/Province
Wisconsin
ZIP/Postal Code
54601
Country
United States
Facility Name
Aurora Health Care
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Vancouver General Hospital, UBC Division of Cardiology
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5N 3W9
Country
Canada
Facility Name
University of Ottawa Heart Institute
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4W7
Country
Canada
Facility Name
Thunder Bay Regional Health Sciences Centre
City
Thunder Bay
State/Province
Ontario
ZIP/Postal Code
P7B 6V4
Country
Canada
Facility Name
Humber River Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M3M 0B2
Country
Canada
Facility Name
Sunnybrook Health Services Center
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Facility Name
St Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Facility Name
Toronto General Hospital - UHN
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 2C4
Country
Canada
Facility Name
Regina General Hospital
City
Regina
State/Province
Saskatchawan
ZIP/Postal Code
S4P 0W5
Country
Canada
Facility Name
Konyang University College of Medicine
City
Daejeon
ZIP/Postal Code
302-718
Country
Korea, Republic of
Facility Name
Chonnam National University Hospital
City
Gwangju
ZIP/Postal Code
501-757
Country
Korea, Republic of
Facility Name
Ajou University Hospital
City
Gyeonggi-do
Country
Korea, Republic of
Facility Name
Chung-Ang University Hospital
City
Seoul
ZIP/Postal Code
156-755
Country
Korea, Republic of
Facility Name
Hospital de Especialidades, Centro Medico Nacional 'La Raza'
City
Mexico City
ZIP/Postal Code
02990
Country
Mexico
Facility Name
Hospital REgional No. 1
City
Mexico City
ZIP/Postal Code
03100
Country
Mexico
Facility Name
Hospital de Cardiologia, Centro Medico Nacional Siglo XXI
City
Mexico City
ZIP/Postal Code
06720
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
32840598
Citation
Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443.
Results Reference
result
PubMed Identifier
35699977
Citation
Avram R, So D, Iturriaga E, Byrne J, Lennon R, Murthy V, Geller N, Goodman S, Rihal C, Rosenberg Y, Bailey K, Farkouh M, Bell M, Cagin C, Chavez I, El-Hajjar M, Ginete W, Lerman A, Levisay J, Marzo K, Nazif T, Olgin J, Pereira N. Patient Onboarding and Engagement to Build a Digital Study After Enrollment in a Clinical Trial (TAILOR-PCI Digital Study): Intervention Study. JMIR Form Res. 2022 Jun 13;6(6):e34080. doi: 10.2196/34080.
Results Reference
derived
PubMed Identifier
35699175
Citation
Madan M, Abbott JD, Lennon R, So DYF, MacDougall AM, McLaughlin MA, Murthy V, Saw J, Rihal C, Farkouh ME, Pereira NL, Goodman SG; TAILOR-PCI Investigators *. Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. J Am Heart Assoc. 2022 Jun 21;11(12):e024709. doi: 10.1161/JAHA.121.024709. Epub 2022 Jun 14.
Results Reference
derived
PubMed Identifier
35449399
Citation
Baudhuin LM, Train LJ, Goodman SG, Lane GE, Lennon RJ, Mathew V, Murthy V, Nazif TM, So DYF, Sweeney JP, Wu AHB, Rihal CS, Farkouh ME, Pereira NL. Point of care CYP2C19 genotyping after percutaneous coronary intervention. Pharmacogenomics J. 2022 Dec;22(5-6):303-307. doi: 10.1038/s41397-022-00278-4. Epub 2022 Apr 21.
Results Reference
derived
PubMed Identifier
35132875
Citation
Capodanno D, Angiolillo DJ, Lennon RJ, Goodman SG, Kim SW, O'Cochlain F, So DY, Sweeney J, Rihal CS, Farkouh M, Pereira NL. ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. J Am Heart Assoc. 2022 Feb 15;11(4):e024156. doi: 10.1161/JAHA.121.024156. Epub 2022 Feb 8.
Results Reference
derived
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Tailored Antiplatelet Therapy Following PCI

We'll reach out to this number within 24 hrs